RS63630B1 - Semaglutid u kardiovaskularnim stanjima - Google Patents

Semaglutid u kardiovaskularnim stanjima

Info

Publication number
RS63630B1
RS63630B1 RS20220901A RSP20220901A RS63630B1 RS 63630 B1 RS63630 B1 RS 63630B1 RS 20220901 A RS20220901 A RS 20220901A RS P20220901 A RSP20220901 A RS P20220901A RS 63630 B1 RS63630 B1 RS 63630B1
Authority
RS
Serbia
Prior art keywords
semaglutide
pharmaceutical composition
use according
subject
mace
Prior art date
Application number
RS20220901A
Other languages
English (en)
Serbian (sr)
Inventor
Oluf Kristian Højbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63630(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS63630B1 publication Critical patent/RS63630B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
RS20220901A 2016-04-28 2017-04-28 Semaglutid u kardiovaskularnim stanjima RS63630B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions
EP17721109.1A EP3448416B1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
RS63630B1 true RS63630B1 (sr) 2022-10-31

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220901A RS63630B1 (sr) 2016-04-28 2017-04-28 Semaglutid u kardiovaskularnim stanjima

Country Status (24)

Country Link
US (3) US12569543B2 (https=)
EP (1) EP3448416B1 (https=)
JP (1) JP7221694B2 (https=)
KR (3) KR102778218B1 (https=)
CN (1) CN109069589B (https=)
AU (2) AU2017256774B2 (https=)
BR (1) BR112018072020A2 (https=)
CA (1) CA3022535A1 (https=)
CL (1) CL2018003045A1 (https=)
DK (1) DK3448416T3 (https=)
ES (1) ES2928007T3 (https=)
HR (1) HRP20221150T1 (https=)
HU (1) HUE060040T2 (https=)
IL (1) IL262390B1 (https=)
MA (1) MA44762A (https=)
MX (1) MX2018012700A (https=)
MY (1) MY202967A (https=)
PH (1) PH12018502274B1 (https=)
PL (1) PL3448416T3 (https=)
RS (1) RS63630B1 (https=)
RU (1) RU2768283C2 (https=)
SI (1) SI3448416T1 (https=)
WO (1) WO2017186896A1 (https=)
ZA (2) ZA202507394B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022535A1 (en) 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
SG11202103137WA (en) * 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
ES2994462T3 (en) * 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
CN119317635A (zh) * 2022-06-08 2025-01-14 载度思生命科学有限公司 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2014066992A1 (en) 2012-11-02 2014-05-08 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP3744327A1 (en) 2013-03-15 2020-12-02 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3022535A1 (en) * 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions

Also Published As

Publication number Publication date
PH12018502274A1 (en) 2019-09-09
ZA202507394B (en) 2025-09-25
EP3448416B1 (en) 2022-08-10
ZA202507395B (en) 2025-09-25
AU2017256774B2 (en) 2024-07-11
US20250288649A1 (en) 2025-09-18
HUE060040T2 (hu) 2023-01-28
KR20250038818A (ko) 2025-03-19
US12569543B2 (en) 2026-03-10
CA3022535A1 (en) 2017-11-02
WO2017186896A1 (en) 2017-11-02
CN109069589B (zh) 2022-09-06
MX2018012700A (es) 2019-01-30
JP2019514925A (ja) 2019-06-06
PH12018502274B1 (en) 2024-02-28
KR20180135012A (ko) 2018-12-19
CN109069589A (zh) 2018-12-21
AU2017256774A1 (en) 2018-11-01
EP3448416A1 (en) 2019-03-06
RU2768283C2 (ru) 2022-03-23
KR20220147712A (ko) 2022-11-03
IL262390A (en) 2018-12-31
PL3448416T3 (pl) 2022-11-07
IL262390B1 (en) 2023-05-01
US20190134162A1 (en) 2019-05-09
DK3448416T3 (da) 2022-10-03
RU2018140900A3 (https=) 2020-09-28
AU2024227113A1 (en) 2024-10-31
JP7221694B2 (ja) 2023-02-14
US20250262281A1 (en) 2025-08-21
KR102778218B1 (ko) 2025-03-10
MA44762A (fr) 2019-03-06
CL2018003045A1 (es) 2018-12-14
SI3448416T1 (sl) 2022-10-28
HRP20221150T1 (hr) 2022-11-25
RU2018140900A (ru) 2020-05-28
BR112018072020A2 (pt) 2019-02-12
ES2928007T3 (es) 2022-11-14
MY202967A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
US20250288649A1 (en) Semaglutide in Cardiovascular Conditions
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
JP7193455B2 (ja) 心血管状態におけるインスリンデグルデク
US20200181222A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
HK1261741B (en) Semaglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
WO2017149105A1 (en) Liraglutide in renal conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions